iSEND免疫评分在晚期非小细胞肺癌免疫联合治疗中的临床意义  

Clinical Significance of iSEND Immune Score in Combinational Immunotherapy for Advanced Non-small Cell Lung Cancer

作　　者：王桂春 张琳 宋阳 尹萍 路中[2] Wang Guichun;Zhang Lin;Song Yang;Yin Ping;Lu Zhong(Clinical Medical College,Weifang Medical University,Weifang 261053,China;Department of Oncology,Affiliated Hospital of Weifang Medical University,Weifang 261053,China)

机构地区：[1]潍坊医学院临床医学院,山东潍坊261053 [2]潍坊医学院附属医院肿瘤科,山东潍坊261042

出　　处：《南开大学学报（自然科学版）》2021年第6期39-45,共7页Acta Scientiarum Naturalium Universitatis Nankaiensis

基　　金：“973”计划(2013CB911100)。

摘　　要：为研究iSEND免疫评分与晚期非小细胞肺癌免疫联合治疗预后之间的关系,选择组织病理学诊断为晚期非小细胞肺癌,且接受免疫检查点抑制剂联合治疗的141例患者作为研究对象.根据患者性别、ECOGPS评分、基线NLR、DNLR计算iSEND免疫评分,按iSEND免疫评分将患者分为两组,iSEND免疫评分=0分为优组,iSEND免疫评分≥1分为中/差组,分析iSEND免疫评分与免疫联合治疗临床预后的相关性.在141例入组患者中,ISEND免疫评分优组60例,评分中/差组81例,优组中位PFS为10.4个月,中/差组的中位PFS只有6.0个月.按不同治疗方案分组,治疗方案为免疫治疗联合化疗组79例,免疫治疗联合化疗和抗血管生成治疗组42例,免疫治疗联合抗血管生成治疗组20例.各免疫联合治疗亚组中,评分优组中位PFS均优于中/差组.因此,iS-END免疫评分可作为预测晚期非小细胞肺癌免疫联合治疗疗效的指标.To investigate whether the iSEND immune score is associated with the clinical efficacy and prognosis of advanced non-small cell lung cancer treated with combinational immunotherapy.Patients with advanced NSCLC treated with combination therapy with immunocheckpoint inhibitors,including immunotherapy combined with chemotherapy,immunotherapy combined with chemotherapy plus antiangiogenesis,and immunotherapy combined with antiangiogenesis,were enrolled.iSEND immune score was calculated according to sex,ECOG PS,baseline neutrophil-to-lymphocyte ratio(NLR),and delta NLR.Patients were categorized into the iSEND groups according to their scores:<1,Good≥1,intermediate or poor.This study enrolled 141 patients.The median PFS was 10.4 months in the iSEND Good group and 6.0 months in the intermediate or poor group.According to different treatment regiments,the treatment regiments includes immunotherapy combined with chemotherapy in 79 cases,immunotherapy combined with chemotherapy plus antiangiogenesis in 42 cases,and immunotherapy combined with antiangiogenesis in 20 cases.In all subgroups of combinational immunotherapy,the median PFS of the iSEND Good group was better than that in the intermediate or poor group.Therefore,iSEND immune score can be used as an indicator to predict the efficacy of combinational immunotherapy for advanced NSCLC.

关 键 词：iSEND免疫评分 非小细胞肺癌 免疫检查点抑制剂 免疫联合治疗 

分 类 号：R734.2[医药卫生—肿瘤]